Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

The head of the U.N. AIDS agency says the sudden loss of American money has been “devastating” for efforts to stop HIV and ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

A new lenacapavir study suggests annual HIV prevention dose; phase three study expected later this year. Lenacapavir injections maintain drug levels for 12 months, exceeding current biannual doses.

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). Gilead presented data on two novel ...